

BUKTI KORESPONDENSI ARTIKEL JURNAL INTERNASIONAL BEREPUTASI


Judul : Dipeptidyl peptidase IV inhibition of phytochemicals from *Artocarpus champeden* (Lour.) Stokes: *In silico* molecular docking study and ADME-Tox prediction approach

Jurnal : Journal of Advanced Pharmaceutical Technology & Research

Penulis : Supandi S, Wulandari MS, Samsul E, Azminah A, Purwoko RY, Herman H, Kuncoro H, Ibrahim A, Silfi Ambarwati NS, Rosmalena R, Azizah RN, Paramita S, Ahmad I

No	Perihal	Tanggal
1	Bukti submit	14-5- 2022
2	Bukti Peer Review	16-5-2022
3	Bukti Review artikel dan rekomendasi publikasi	23-5-2022
4	Bukti proof	10-6-2022
5	Bukti publikasi	23-7-2022

Author New Submission Acknowledgement letter: **japtr_376_22**

 Journal of Advanced Pharmaceutical Technology & Research<editor@japtr.org>
To: You Sat 5/14/2022 8:44 PM

Dear Dr. Dr. Islamudin Ahmad,

Journal of Advanced Pharmaceutical Technology & Research has received your manuscript entitled "Dipeptidyl peptidase IV inhibition of phytochemicals from *Artocarpus champeden* (Lour.) Stokes: *In silico* molecular docking study and ADME-Tox prediction approach" for consideration for publication. The reference number for this manuscript is **japtr_376_22**. Kindly quote this in future correspondences related to this manuscript.

The manuscript is being reviewed for possible publication with the understanding that it is being submitted to ONE journal at a time and has NOT been published, simultaneously submitted, or already accepted for publication elsewhere either as a whole or in a part.

Online submission of this article implies that the corresponding author has written consent from all the contributors to act as the corresponding author.

The co-authors are requested to send their agreement response on the **Digital Copyright** sent via a link to their associated emails, within 1 week of submission. The status can be viewed in the 'Manuscript Information page' from the submitting author's area. The decision about the manuscript will be conveyed only on receipt of the agreement on copyright form received from all contributors.

High-resolution images are required at the time of acceptance, you should be notified separately for the same if images uploaded by you are not of printable quality.

The Editors will review the submitted manuscript initially. If found suitable, it will follow a double-blinded peer review. We aim to finish this review process within a short time frame, at the end of which a decision on the suitability or otherwise of the manuscript will be conveyed to you via this system.

During this process, you are free to check the progress of the manuscript through various phases from our online manuscript processing site <https://review.jow.medknow.com/japtr>.

We thank you for submitting your valuable work to the Journal of Advanced Pharmaceutical Technology & Research.

Yours sincerely,
Editorial Team
Journal of Advanced Pharmaceutical Technology & Research

Manuscript for revision: **japtr_376_22**



Journal of Advanced Pharmaceutical Technology & Research <editor@japtr.org>

To: You



Mon 5/16/2022 12:58 AM

Dear Dr. Ahmad,

With reference to your manuscript **japtr_376_22** entitled Dipeptidyl peptidase IV inhibition of phytochemicals from *Artocarpus champeden* (Lour.) Stokes: In silico molecular docking study and ADME-Tox prediction approach, please review the comments of the referees from our site <https://review.jaw.medknow.com/japtr>. The manuscript would be reconsidered after requisite modifications as per the comments and instructions provided by the journal.

If you wish to continue with the publication process, kindly make the changes according to the comments and upload the revised manuscript along with clarifications for all the comments clearly indicating the areas where the changes have been made.

Do check the FAQ regarding replying to the comments and uploading a file. The template of point-by-point comments files for the reviewers, is available in your dashboard under the 'Downloads' menu option.

The journal allows two weeks for the revision of the manuscript. If we do not hear from you within this period, we will consider it as your decision to withdraw your article from publication. Please also note that the submission of the revised article does not guarantee its final acceptance by the journal.

We thank you for submitting your valuable research work to Journal of Advanced Pharmaceutical Technology & Research.

With warm personal regards,

Editorial Team

Journal of Advanced Pharmaceutical Technology & Research

Reply Forward

Reply to the reviewers' comments

Reviewer Number	Original comments of the reviewer	Reply by the author(s)	Changes done on page number and line number
1	The similarity index should be less than 15% and the primary source index should be 1% or less than 1%. We have attached the similarity report.	We already revised and checked the Turnitin and have complied with the requirements	The entire manuscript
2	The methodology should be given properly and highlighted.	We already revised	Method section
3	The manuscript should be RESTRICTED within 3000 words including everything.	We already revised	The entire manuscript (2981 words)
4	Some recent relevant references should be given from 2022	We already added relevant references (2022)	Page no. 14 references section (no. 21 and 22)
5	Language needs to be improved in the entire manuscript, and grammatical errors should be corrected.	We already revised and improved in the entire manuscript, also corrected the grammatical error	The entire manuscript
6	References should be given strictly as per the journal's instructions.	We already revised	References section

Author-side fee of your manuscript **japtr_376_22**

 Journal of Advanced Pharmaceutical Technology & Research <editor@japtr.org>
To: You


Thu 5/19/2022 7:48 PM

Dear Dr Ahmad,

We are pleased to inform that your manuscript "Dipeptidyl peptidase IV inhibition of phytochemicals from Artocarpus champeden (Lour.) Stokes: In silico molecular docking study and ADME-Tox prediction approach" is now acceptable after clearing the dues of USD 700 for publication of the manuscript.

The payment can be done using the following link:

<https://subscriptions.medknow.com/api/payments.asp?API Caller=UNIPBR>

The following options are available for payment:

- Pay online
- Cheque payment
- Wire transfer

Once the payment is received at our end, the manuscript would be processed further and you would receive an edited version of article in about 2-3 weeks from now for a final check and correction.

We thank you for submitting your valuable research work to Journal of Advanced Pharmaceutical Technology & Research.

- With warm personal regards,

Yours sincerely,
Editorial Team
Journal of Advanced Pharmaceutical Technology & Research

 Reply  Forward

Author-side fee received... **japtr_376_22**


 Journal of Advanced Pharmaceutical Technology & Research <editor@japtr.org>
To: You


Mon 5/23/2022 9:38 PM

Dear Dr Ahmad,

We have received the payment for "Dipeptidyl peptidase IV inhibition of phytochemicals from Artocarpus champeden (Lour.) Stokes: In silico molecular docking study and ADME-Tox prediction approach" and you would receive an edited version of article in about 2-3 weeks from now for a final check and correction.

Editorial Team
Journal of Advanced Pharmaceutical Technology & Research

 Reply  Forward

Manuscript for Final Proof Uploaded: [japtr_376_22](#)



Journal of Advanced Pharmaceutical Technology & Research <editor@japtr.org>

To: You



Fri 4/10/2022 8:42 PM

Dear Dr Ahmad

Thank you for completing proofing Journal of Advanced Pharmaceutical Technology & Research [japtr_376_22](#) Dipeptidyl peptidase IV inhibition of phytocompounds from Artocarpus champeden (Lour.) Stokes: In silico molecular docking study and ADME-Tox prediction approach through the manuscript management site before publication of the manuscript.

We shall get back to you soon for any further corrections.

Please note that the journal reserves the right to make changes in the language, grammar, presentation, etc. to suit the journal's requirements.

We thank you for submitting your valuable research work to Journal of Advanced Pharmaceutical Technology & Research.

With warm personal regards,

Yours sincerely,

The Editorial Team

Journal of Advanced Pharmaceutical Technology & Research

Reply

Forward

Proofs corrections

Journal Journal of Advanced Pharmaceutical Technology & Research

Article title Dipeptidyl peptidase IV inhibition of phytocompounds from *Artocarpus champeden* (Lour.) Stokes: *In silico* molecular docking study and ADME-Tox prediction approach

I would like to recheck the corrections: Yes / ~~No~~

If you have access to Acrobat, it may be helpful to mark the corrections in the PDF file using PENCIL and NOTE tools. Alternatively provide the list of corrections using this table. Please make the corrections' list self-explanatory and easy to understandable for a non-medical technical person.

List of corrections

Page number	Column (Left / Right)	Paragraph number from top	Line number from top of paragraph	Delete this text (Error)	Replace deleted text with (correction)
4	AQ1:			Kindly provide part label in figure	Already added label in figure
1	AQ2:	Author name		Kindly provide the author full name. Supandi Herman Rosmalena	Supandi S, Herman H, Rosmalena R,
1	AQ3			The author "Supandi" has not agreed to the copyright terms and conditions which was sent on the authors email address.	Has been checked
1	AQ4			Kindly check the author name provided in New System "Herman Herman." Please confirm	Has been changed
1	AQ5			The author "Neneng Siti Silfi Ambarwati" has not agreed to the copyright terms and conditions which was sent on the authors email address.	Has been checked

1	AQ6			Kindly check the author name provided in New System "Rosmalena Sofyan." Please confirm.	Has been changed
1	AQ7			Kindly provide the department	Has been added
1	AQ8			Kindly check the affiliation.	Ok
8	AQ9			Please provide publisher location. de Almeida Lopes MM, de Souza KO, de Oliveira Silva E. Cempedak - <i>Artocarpus champeden</i> , in de Brito E, Rodrigues S, and de Oliveira Silva E. 1st Edition. Exotic Fruits Reference Guide. London: Academic Press: 2018; 121-7. "	de Almeida Lopes MM, de Souza KO, de Oliveira Silva E. Cempedak - <i>Artocarpus champeden</i> , in de Brito E, Rodrigues S, and de Oliveira Silva E. 1st Edition. Exotic Fruits Reference Guide. London: Academic Press: 2018; 121-7. "
8-9	AQ10	Reference	Poin 2 Poin 5 Poin 13 Poin 18	Kindly check the affiliation. Suyatno. Subehan, Sukardiman, Suharjono. Harizal, Herman,	Suyatno S. Subehan S, Sukardiman S, Suharjono S. Harizal H, Herman H,
1	Left column	Afiliation	28-31	Department of Community Medicine, Research Center of Natural Products from Tropical Rainforest, Faculty of Medicine, Universitas Mulawarman	Department of Community Medicine, Faculty of Medicine, and Research Center of Natural Products from Tropical Rainforest, Universitas Mulawarman,"
4	Left column	3	12	DPPIV	DPP-IV
4	Left column	4	16	DPPIV	DPP-IV
4	Right column	1	14	DPPIV	DPP-IV
4	Right Column	2	22-23	artoindonesian B,	Artoindonesianin B,
4	Right Column	3	36-37	Artoindonesia A, artoindonesian A3,	Artoindonesianin A,

				artoindonesian B, artoindonesian R,	artoindonesianin A3, artoindonesianin B, artoindonesianin R,
--	--	--	--	--	--

Dipeptidyl peptidase IV inhibition of phytocompounds from *Artocarpus champeden* (Lour.) Stokes: *In silico* molecular docking study and ADME-Tox prediction approach

Supandi¹, Lesy Savira Wulandari¹,
Erwin Samsul¹, Azminah Azminah²,
Reza Yuridian Purwoko³, Herman⁴,
Hadi Kuncoro¹, Arsyik Ibrahim⁵,
Neneng Siti Silfi Ambarwati⁶,
Rosmala⁷, Rizqi Nur Azizah⁸,
Swandari Paramita⁹, Islamudin Ahmad¹

¹Faculty of Pharmacy and Science,
Universitas Muhammadiyah Prof.
Dr. HAMKA, ²Department of Medical
Chemistry, Faculty of Medicine,
Universitas Indonesia, South Jakarta,
³Indonesian Research and
Innovation Agency, ⁴Department of
Cosmetology, Engineering Faculty,
Universitas Negeri Jakarta, East
Jakarta, Jakarta, ⁵Department of
Pharmaceutical Sciences, Faculty of
Pharmacy, Universitas Mulawarman,
⁶Department of Community Medicine,
Research Center of Natural Products
from Tropical Rainforest, Faculty of
Medicine, Universitas Mulawarman,
Samarinda, East Kalimantan, ⁷Faculty of Pharmacy, University of
Surabaya, Surabaya, ⁸Faculty
of Pharmacy, Universitas Islam
Indonesia, Makassar, South Sulawesi,
Indonesia

J. Adv. Pharm. Technol. Res.

ABSTRACT

The present study examines the potential activity prediction based on free binding energy (ΔG) and interaction confirmation of phytocompounds from *Artocarpus champeden* (Lour.) Stokes with macromolecule protein receptor of dipeptidyl peptidase IV (DPP-IV) using *in silico* molecular docking studies and physicochemical and pharmacokinetic properties (ADME-Tox) prediction approaches. The active subsites of the DPP-IV receptor macromolecule protein Protein Data Bank (ID: 1 × 70) were docked using Autodock v4.2.6 (100 docking runs). A grid box of $52 \times 28 \times 26$ Å points spaced by 0.37 Å was centered on the active site of $x = 40.926$ Å; $y = 50.522$ Å; $z = 35.031$ Å. For ADME-Tox prediction, Swiss ADME online-based application programs were used. The results show that 12 phytocompounds from *A. champeden* have the potential as DPP-IV inhibitors based on ΔG value and interaction conformation. There are five phytocompounds with lower ΔG values and inhibition constants than the native ligand and seven phytocompounds with ΔG values and inhibition constants close to the native ligand. The 12 compounds form an interaction conformation at the active subsites of the DPP-IV receptor. At the same time, the results of the ADME-Tox prediction analysis showed that the 12 compounds had different physicochemical and pharmacokinetic properties.

Key words: ADME-tox, *Artocarpus champeden* (Lour.) stokes, dipeptidyl peptidase IV, free binding energy, *in silico* molecular docking

INTRODUCTION

Artocarpus champeden (Lour.) Stokes belongs to the Moraceae family, locally known as "Chempedak," an annual fruit plant with a tall, strong woody tree. This fruit plant is a native that grows wild in tropical forests, mainly in India,

Address for correspondence:

Dr. Islamudin Ahmad,
Jl. Kuaro Gn. Kelua, Samarinda 75119 East Kalimantan,
Indonesia.
E-mail: islamudinahmad@farmasi.unmul.ac.id

Submitted: 14-May-2022

Revised: 18-May-2022

Accepted: 23-May-2022

Published: ***

Access this article online

Quick Response Code:



Website:

www.japtr.org

DOI:

10.4103/japtr.japtr_376_22

This is an open access journal, and articles are distributed under the terms of the Creative Commons Attribution-NonCommercial-ShareAlike 4.0 License, which allows others to remix, tweak, and build upon the work non-commercially, as long as appropriate credit is given and the new creations are licensed under the identical terms.

For reprints contact: WKHLRPMedknow_reprints@wolterskluwer.com

How to cite this article: Supandi, Wulandari MS, Samsul E, Azminah A, Purwoko RY, Herman, *et al.* Dipeptidyl peptidase IV inhibition of phytocompounds from *Artocarpus champeden* (Lour.) Stokes: *In silico* molecular docking study and ADME-Tox prediction approach. J Adv Pharm Technol Res 2022;XX:XX-XX.

Vietnam, Myanmar, Thailand, Malaysia, and Indonesia.^[1] This plant is widespread in Sumatran, Kalimantan, Sulawesi, Maluku, and West Papua in Indonesia. Traditionally, this plant treats diarrhea, fever, malaria, and diabetes mellitus. However, no scientific evidence has been reported of *A. champeden* as a potential antidiabetic agent to the best of our knowledge. Therefore, our team is interested in researching the potential of this plant.

Meanwhile, several studies have isolated and identified phytocompounds found in *A. champeden*.^[2-5] However, data regarding the potential pharmacological activity of phytocompounds from *A. champeden* is still minimal, mainly as antidiabetic, whereas it has traditionally been used for generations. This series of work fills research gaps by examining the potential activity and interactions of phytocompound from *A. champeden* using the *in silico* molecular docking study and ADME-Tox prediction approach.

In silico molecular docking is a modeling method based on computer simulation to search for possible bindings of the test ligand and receptor-interacting under topographical conditions and the match between both molecules with the conformation that has the best interaction.^[6-9] ADME-Tox prediction is performed using an online-based application such as SWISSADME, which aims to study physicochemical and pharmacokinetic properties.^[10,11] Some studies that have been reported successfully related to the use of these application programs include ADMET analysis of three relevant natural components of the medicinal plant,^[12] ADMET prediction of mangosteen derivatives,^[13] ADME-Tox prediction of phytocompounds from *Merremia peltata*,^[14] and drug-likeness prediction of bioactive compounds from *Punica granatum* L.^[15]

The current study predicts the interaction conformation and the potential activity of phytocompounds from *A. champeden* with macromolecules protein of dipeptidyl peptidase IV (DPP-IV) as a receptor target, hoping to fill research gaps on an *in silico* assay scale, thereby accelerating the development of further studies.

MATERIALS AND METHODS

Hardware and software

The analysis of molecular docking was carried out by a computer HP Pavilion, Autodock-v4.2.6, AutodockTools, ChemOffice-Pro-v15.00 PerkinElmer, Phyton Molecular Viewer (PMV-1.5.6), OpenBabel GUI, Accelrys Discovery Studio Visualizer 4.0. Software, and SWISSADME (<http://www.swissadme.ch/>) online tools program.

In silico molecular docking study

Native ligand and receptor preparation

The protein structure of macromolecule DPP-IV complexes with native ligand sitagliptin Protein Data Bank (PDB ID:

1 × 70, with 2.1 Å resolution) was downloaded from the Research Collaboratory for Structural Bioinformatics PDB via the website: <https://www.rcsb.org/>. Macromolecule DPP-IV receptors and native ligand were separated using PMV-1.5.6. Gasteiger charges were added to each ligand atom. Water molecules were eliminated from each protein receptor and protonated. Then, a native ligand and protein receptor was prepared and converted in the PDBQT format (.pdbqt) using AutodockTools and OpenBabel programs.^[17,16]

Preparation of phytocompounds as a test ligand

In this study, the structure of phytocompounds from *A. champeden* was collected from some literature,^[2-5] as shown in Figure 1. Each phytocompounds were prepared as a test ligand using ChemDraw® Pro v15 to build a two-dimension structure of each phytocompounds. Chem three-dimensional (3D)® Pro v15 was converted to a 3D structure, minimized using the MMFF94 force field, and saved to PDB (.pdb).^[18]

Analysis of *in silico* molecular docking

According to its protocols, the analysis of *in silico* molecular docking of 41 phytocompounds from *A. champeden* was conducted using Autodock 4.2.6.^[17] Using the Lamarckian Genetic Algorithm (LGA) based on the lowest free energy of binding (ΔG), the native ligand was simulated in various conformations for best binding to the protein DPP-IV receptor binding site. The parameters of LGA were: elitism of 1, crossover rate of 0.8, the mutation rate of 0.02, the population size of 150, energy evaluation of 2500,000, and 100 runs. Moreover, the grid box comprised of 52 × 28 × 26 Å points spaced by 0.375 Å was centered on the active site of x = 40.926 Å; y = 50.522 Å; z = 35.031 Å (XYZ-coordinates) according to a previous study.^[17] The grid condition was used for molecular docking analysis of 41 phytocompounds from *A. champeden*. The results of molecular docking data were visualized using Accelrys Discovery Studio Visualizer-4.0.^[18]

Determination of ADME-tox prediction

According to the literature, ADME-Tox prediction of the best docking results was determined using SWISSADME online tools.^[11] Briefly, each phytocompounds (PDB format) structure was converted in SMILES format using OpenBabel GUI. SWISSADME online tools program was used to determine ADME-Tox of 12 phytocompounds.^[18]

RESULTS

In silico molecular docking study

Validation of molecular docking method

In the present study, the docking results of the native ligand (sitagliptin) demonstrated a root mean square deviation (RMSD) value of 0.55 Å (<2 Å) with a binding free energy (ΔG) value of -8.59 kcal/mol (inhibition constant




Figure 1: 2D structure of phytocompounds from *Artocarpus champeden*. 2D: Two-dimension

of 508.58 nM) and clusters of 82% for 100 times running. Figure 2 shows that the overlay position between the

docking results and the original native ligand does not significantly different positions according to the RMSD

value $<2 \text{ \AA}$, indicating that the grid size and grid center of the docking process was different valid.

The docking results of 41 phytocompounds from *A. champeden* in Table 1 show that five compounds had a lower ΔG value and inhibition constant than the native ligand. Seven compounds have ΔG value and inhibition constant close to the native ligand.

Studies on molecular interaction

Figure 3 demonstrates visualization of native ligand interaction with active site residue of DPP-IV macromolecule receptors.

In Figure 4, it was shown that 12 phytocompounds have conformational interactions with subsites of the DPP-IV receptor.

ADME-tox prediction

The ADME-Tox properties prediction of selected 12 phytocompounds from *A. champeden* according to the molecular docking study is presented in Table 2. The physicochemical properties prediction provides an overview of bioavailability levels of phytocompounds, as shown in Figure 5.




Figure 2: Visualization of original (yellow) and re-docked (green) native ligand overlay position

DISCUSSION

The result of re-docking of native ligand indicates the level of validity of grid box and box size used with an RMSD value of 0.55 \AA ($<2 \text{ \AA}$), which refers to the previous study,^[17,19] indicating that the grid size and grid center of the docking process was different valid. The docking result demonstrated native ligand and test ligand interaction with the active site of DPP-IV receptor macromolecules. The DPP-IV receptor has some active site areas at subsites area of amino acid residues known as S_1 , S_1' , S_2' , S_2 , and S_2 extensive.^[20-22] The test ligand activity can generally be predicted based on interactions at subsites (S_1 , S_2 , and S_2 ext.) of the DPP-IV receptor.^[21,22]

In this study, it was found that five phytocompounds had lower ΔG values than the native ligand, including 24-methylcycloartanon, cycloartenon, cycloartenol, β -sitosterol, and cycloeucalenol, and seven phytocompounds that had an ΔG value close to the native ligand include cudraflavon C, artoindonesianin A, 5'-hydroxycudraflavon A, artoindonesianin B, artoindonesianin R, artoindonesianin A3, and cyclocommunim. In addition, the 12 phytocompounds showed conformational interactions that were specific to the active subsite of the DPP-IV receptor. Each amino acid residue of the active subsites of the DPP-IV receptor can form seven different interaction conformations with the test ligand.^[23]

The ADME-Tox properties play a crucial role in the drug industry. They are generally used in drug development, mainly using the computer-aided drug design approach to reduce unwanted effects. 24-Methylcycloartanon has an MW value that is in the unacceptable range, while the others are in the acceptable range. Artoindonesianin A3, artoindonesianin B, artoindonesianin R, cudraflavon C, cyclocommunin, and 5'-hydroxycudraflavon A obey the Lipinski rule, except six other compounds (RO5 value >0).^[24]




Figure 3: Visualization of (a) two-dimension and (b) three-dimension of molecular interaction between native ligand against macromolecule of DPP-IV receptor (PDB ID: 1X70). PDB: Protein Data Bank, DPP-IV: Dipeptidyl peptidase IV

Table 1: Docking results characteristic and ligand-receptor interaction

Ligand	ΔG value (kcal/mol)	Inhibition constant (nM)	Interaction
Sitagliptin (native)	-8.59	508.58	His ⁷⁴⁰ ; Val ⁷¹¹ ; Asn ⁷¹⁰ ; Tyr ⁶⁶⁶ ; Tyr ⁶⁶² ; Trp ⁶⁵⁹ ; Val ⁶⁵⁶ ; Tyr ⁶³¹ ; Ser ⁶³⁰ ; Tyr ⁵⁴⁷ ; Arg ³⁵⁸ ; Phe ³⁵⁷ ; Ser ²⁰⁹ ; Phe ²⁰⁸ ; Val ²⁰⁷ ; Glu ²⁰⁶ ; Glu ²⁰⁵ ; Arg ¹²⁵
24-methylcycloartanon	-10.77	12.16	His ⁷⁴⁰ ; Val ⁷¹¹ ; Asn ⁷¹⁰ ; Arg ⁶⁶⁹ ; Tyr ⁶⁶⁶ ; Tyr ⁶⁶² ; Trp ⁶⁵⁹ ; Val ⁶⁵⁶ ; Tyr ⁶³¹ ; Ser ⁶³⁰ ; Tyr ⁵⁴⁷ ; Arg ³⁵⁸ ; Phe ³⁵⁷ ; Ser ²⁰⁹ ; Val ²⁰⁷ ; Glu ²⁰⁶ ; Glu ²⁰⁵ ; Arg ¹²⁵
Artobioxanton	-6.92	8520	Tyr ⁶⁷⁰ ; Tyr ⁶⁶⁶ ; Tyr ⁶⁶² ; Tyr ⁶³⁰ ; Ser ⁵⁵² ; Pro ⁵⁵⁰ ; Gly ⁵⁴⁹ ; Tyr ⁵⁴⁷ ; Arg ³⁵⁸ ; Phe ³⁵⁷ ; Ser ²⁰⁹ ; Phe ²⁰⁸ ; Val ²⁰⁷ ; Glu ²⁰⁶ ; Glu ²⁰⁵
Artocarpanon	-6.13	32070	His ⁷⁴⁰ ; Val ⁷¹¹ ; Asn ⁷¹⁰ ; Arg ⁶⁶⁹ ; Tyr ⁶⁶⁶ ; Tyr ⁶⁶² ; Val ⁶⁵⁶ ; Tyr ⁶³¹ ; Ser ⁶³⁰ ; Tyr ⁵⁴⁷ ; Phe ³⁵⁷ ; Ser ²⁰⁹ ; Val ²⁰⁷ ; Glu ²⁰⁶ ; Glu ²⁰⁵ ; His ¹²⁶ ; Arg ¹²⁵
Artocarpin	-6.95	7990	His ⁷⁴⁰ ; Val ⁷¹¹ ; Asn ⁷¹⁰ ; Arg ⁶⁶⁹ ; Tyr ⁶⁶⁶ ; Tyr ⁶⁶² ; Val ⁶⁵⁶ ; Tyr ⁶³¹ ; Ser ⁶³⁰ ; Tyr ⁵⁴⁷ ; Phe ³⁵⁷ ; Ser ²⁰⁹ ; Val ²⁰⁷ ; Glu ²⁰⁶ ; Glu ²⁰⁵ ; His ¹²⁶ ; Arg ¹²⁵
Artocarpon A	-7.76	2040	His ⁷⁴⁰ ; Val ⁷¹¹ ; Asn ⁷¹⁰ ; Arg ⁶⁶⁹ ; Tyr ⁶⁶⁶ ; Tyr ⁶⁶² ; Tyr ⁶³¹ ; Ser ⁶³⁰ ; Ser ⁵⁵² ; Pro ⁵⁵⁰ ; Gly ⁵⁴⁹ ; Tyr ⁵⁴⁷ ; Phe ³⁵⁷ ; Ser ²⁰⁹ ; Glu ²⁰⁶ ; Glu ²⁰⁵ ; Arg ¹²⁵
Artocarpon B	-6.82	9990	Asn ⁷¹⁰ ; Arg ⁶⁶⁹ ; Tyr ⁶⁶⁶ ; Tyr ⁶⁶² ; Tyr ⁵⁴⁷ ; Arg ³⁵⁸ ; Phe ³⁵⁷ ; Ser ²⁰⁹ ; Val ²⁰⁷ ; Glu ²⁰⁶ ; Glu ²⁰⁵ ; Arg ¹²⁵
Artoindonesianin A	-8.50	592	Asn ⁷¹⁰ ; Arg ⁶⁶⁹ ; Tyr ⁶⁶⁶ ; Tyr ⁶⁶² ; Tyr ⁶³¹ ; Ser ⁶³⁰ ; Tyr ⁵⁸⁵ ; Ser ⁵⁵² ; Cys ⁵⁵¹ ; Pro ⁵⁵⁰ ; Gly ⁵⁴⁹ ; Tyr ⁵⁴⁷ ; Arg ³⁵⁸ ; Phe ³⁵⁷ ; Arg ³⁵⁶ ; Ser ²⁰⁹ ; Val ²⁰⁷ ; Glu ²⁰⁶ ; Glu ²⁰⁵ ; Arg ¹²⁵
Artoindonesianin A2	-6.20	28340	Arg ⁶⁶⁹ ; Tyr ⁶⁶⁶ ; Asp ⁶⁶³ ; Tyr ⁶⁶² ; Tyr ⁶³¹ ; Ser ⁶³⁰ ; Tyr ⁵⁴⁷ ; Phe ³⁵⁷ ; Ser ²⁰⁹ ; Val ²⁰⁷ ; Glu ²⁰⁶ ; Glu ²⁰⁵ ; His ¹²⁶ ; Arg ¹²⁵
Artoindonesianin A3	-8.06	1240	His ⁷⁴⁰ ; Val ⁷¹¹ ; Arg ⁶⁶⁹ ; Tyr ⁶⁶⁶ ; Tyr ⁶⁶² ; Trp ⁶⁵⁹ ; Val ⁶⁵⁶ ; Tyr ⁶³¹ ; Ser ⁶³⁰ ; Tyr ⁵⁴⁷ ; Arg ³⁵⁸ ; Phe ³⁵⁷ ; Ser ²⁰⁹ ; Val ²⁰⁷ ; Glu ²⁰⁶ ; Glu ²⁰⁵ ; Arg ¹²⁵
Artoindonesianin B	-8.14	1080	His ⁷⁴⁰ ; Val ⁷¹¹ ; Arg ⁶⁶⁹ ; Tyr ⁶⁶⁶ ; Tyr ⁶⁶² ; Val ⁶⁵⁶ ; Tyr ⁶³¹ ; Ser ⁶³⁰ ; Tyr ⁵⁴⁷ ; Arg ³⁵⁸ ; Phe ³⁵⁷ ; Ser ²⁰⁹ ; Phe ²⁰⁸ ; Val ²⁰⁷ ; Glu ²⁰⁶ ; Glu ²⁰⁵ ; Arg ¹²⁵
Artoindonesianin E	-6.26	25580	Arg ⁶⁶⁹ ; Tyr ⁶⁶⁶ ; Tyr ⁶⁶² ; Ser ⁵⁵² ; Pro ⁵⁵⁰ ; Gly ⁵⁴⁹ ; Tyr ⁵⁴⁷ ; Arg ³⁵⁸ ; Phe ³⁵⁷ ; Ser ²⁰⁹ ; Val ²⁰⁷ ; Glu ²⁰⁶ ; Glu ²⁰⁵
Artoindonesianin M	-7.39	3850	Arg ⁶⁶⁹ ; Tyr ⁶⁶⁶ ; Tyr ⁶⁶² ; Ser ⁶³⁰ ; Tyr ⁵⁴⁷ ; Arg ³⁵⁸ ; Phe ³⁵⁷ ; Ser ²⁰⁹ ; Phe ²⁰⁸ ; Val ²⁰⁷ ; Glu ²⁰⁶ ; Glu ²⁰⁵ ; Arg ¹²⁵
Artoindonesianin Q	-7.19	5370	His ⁷⁴⁰ ; Val ⁷¹¹ ; Arg ⁶⁶⁹ ; Tyr ⁶⁶⁶ ; Asp ⁶⁶³ ; Tyr ⁶⁶² ; Trp ⁶⁵⁹ ; Val ⁶⁵⁶ ; Tyr ⁶³¹ ; Ser ⁶³⁰ ; Tyr ⁵⁴⁷ ; Arg ³⁵⁸ ; Phe ³⁵⁷ ; Ser ²⁰⁹ ; Val ²⁰⁷ ; Glu ²⁰⁶ ; Glu ²⁰⁵ ; His ¹²⁶ ; Arg ¹²⁵
Artoindonesianin R	-8.10	1160	His ⁷⁴⁰ ; Val ⁷¹¹ ; Asn ⁷¹⁰ ; Arg ⁶⁶⁹ ; Tyr ⁶⁶⁶ ; Tyr ⁶⁶² ; Tyr ⁶³¹ ; Ser ⁶³⁰ ; Ser ⁵⁵² ; Pro ⁵⁵⁰ ; Gly ⁵⁴⁹ ; Tyr ⁵⁴⁷ ; Phe ³⁵⁷ ; Ser ²⁰⁹ ; Val ²⁰⁷ ; Glu ²⁰⁶ ; Glu ²⁰⁵ ; His ¹²⁶ ; Arg ¹²⁵
Artoindonesianin S	-6.60	14410	His ⁷⁴⁰ ; Arg ⁶⁶⁹ ; Tyr ⁶⁶⁶ ; Tyr ⁶⁶² ; Trp ⁶⁵⁹ ; Val ⁶⁵⁶ ; Tyr ⁶³¹ ; Ser ⁶³⁰ ; Tyr ⁵⁴⁷ ; Phe ³⁵⁷ ; Ser ²⁰⁹ ; Val ²⁰⁷ ; Glu ²⁰⁶ ; Glu ²⁰⁵ ; His ¹²⁶ ; Arg ¹²⁵
Artoindonesianin T	-6.22	27750	His ⁷⁴⁰ ; Arg ⁶⁶⁹ ; Tyr ⁶⁶⁶ ; Tyr ⁶⁶² ; Trp ⁶⁵⁹ ; Tyr ⁶³¹ ; Ser ⁶³⁰ ; Tyr ⁵⁴⁷ ; Ser ²⁰⁹ ; Val ²⁰⁷ ; Glu ²⁰⁶ ; Glu ²⁰⁵ ; His ¹²⁶ ; Arg ¹²⁵
Artoindonesianin U	-6.08	34950	His ⁷⁴¹ ; Val ⁷¹¹ ; Asn ⁷¹⁰ ; Arg ⁶⁶⁹ ; Tyr ⁶⁶⁶ ; Tyr ⁶⁶² ; Tyr ⁶³¹ ; Ser ⁶³⁰ ; Ser ⁵⁵² ; Pro ⁵⁵⁰ ; Gly ⁵⁴⁹ ; Tyr ⁵⁴⁷ ; Phe ³⁵⁷ ; Ser ²⁰⁹ ; Glu ²⁰⁶ ; Glu ²⁰⁵ ; Arg ¹²⁵
Artoindonesianin V	-7.73	2140	His ⁷⁴¹ ; Val ⁷¹¹ ; Asn ⁷¹⁰ ; Arg ⁶⁶⁹ ; Tyr ⁶⁶⁶ ; Tyr ⁶⁶² ; Tyr ⁶³¹ ; Ser ⁶³⁰ ; Ser ⁵⁵² ; Pro ⁵⁵⁰ ; Gly ⁵⁴⁹ ; Tyr ⁵⁴⁷ ; Phe ³⁵⁷ ; Ser ²⁰⁹ ; Glu ²⁰⁶ ; Glu ²⁰⁵ ; Arg ¹²⁵
Artonin A	-7.95	1490	His ⁷⁴⁰ ; Val ⁷¹¹ ; Asn ⁷¹⁰ ; Arg ⁶⁶⁹ ; Tyr ⁶⁶⁶ ; Tyr ⁶⁶² ; Tyr ⁶³¹ ; Ser ⁶³⁰ ; Tyr ⁵⁴⁷ ; Arg ³⁵⁸ ; Phe ³⁵⁷ ; Ser ²⁰⁹ ; Val ²⁰⁷ ; Glu ²⁰⁶ ; Glu ²⁰⁵ ; Arg ¹²⁵
Artonin B	-7.60	2700	Tyr ⁶⁶⁶ ; Tyr ⁶⁶² ; Tyr ⁶³¹ ; Tyr ⁵⁸⁵ ; Ser ⁵⁵² ; Cys ⁵⁵¹ ; Pro ⁵⁵⁰ ; Gly ⁵⁴⁹ ; Tyr ⁵⁴⁷ ; Arg ³⁵⁸ ; Phe ³⁵⁷ ; Arg ³⁵⁶ ; Ser ²⁰⁹ ; Glu ²⁰⁶ ; Glu ²⁰⁵ ; Arg ¹²⁵
Artonin E	-7.70	2250	His ⁷⁴⁰ ; Asn ⁷¹⁰ ; Arg ⁶⁶⁹ ; Tyr ⁶⁶⁶ ; Tyr ⁶⁶² ; Ser ⁶³⁰ ; Pro ⁵⁵⁰ ; Gly ⁵⁴⁹ ; Tyr ⁵⁴⁷ ; Arg ³⁵⁸ ; Phe ³⁵⁷ ; Ser ²⁰⁹ ; Phe ²⁰⁸ ; Val ²⁰⁷ ; Glu ²⁰⁶ ; Glu ²⁰⁵ ; Arg ¹²⁵
β -sitosterol	-9.97	49.17	His ⁷⁴⁰ ; Val ⁷¹¹ ; Asn ⁷¹⁰ ; Arg ⁶⁶⁹ ; Tyr ⁶⁶⁶ ; Tyr ⁶⁶² ; Trp ⁶⁵⁹ ; Val ⁶⁵⁶ ; Tyr ⁶³¹ ; Ser ⁶³⁰ ; Tyr ⁵⁴⁷ ; Arg ³⁵⁸ ; Phe ³⁵⁷ ; Ser ²⁰⁹ ; Phe ²⁰⁸ ; Val ²⁰⁷ ; Glu ²⁰⁶ ; Glu ²⁰⁵ ; Arg ¹²⁵
Chaplasin	-7.21	5160	His ⁷⁴⁰ ; Val ⁷¹¹ ; Arg ⁶⁶⁹ ; Tyr ⁶⁶⁶ ; Tyr ⁶⁶² ; Trp ⁶⁵⁹ ; Val ⁶⁵⁶ ; Tyr ⁶³¹ ; Ser ⁶³⁰ ; Tyr ⁵⁴⁷ ; Arg ³⁵⁸ ; Phe ³⁵⁷ ; Ser ²⁰⁹ ; Val ²⁰⁷ ; Glu ²⁰⁶ ; Glu ²⁰⁵ ; Arg ¹²⁵
Cudraflavon C	-8.53	558.13	Val ⁷¹¹ ; Arg ⁶⁶⁹ ; Tyr ⁶⁶⁶ ; Tyr ⁶⁶² ; Trp ⁶⁵⁹ ; Val ⁶⁵⁶ ; Tyr ⁶³¹ ; Ser ⁶³⁰ ; Tyr ⁵⁸⁵ ; Tyr ⁵⁴⁷ ; Arg ³⁵⁸ ; Phe ³⁵⁷ ; Ser ²⁰⁹ ; Val ²⁰⁷ ; Glu ²⁰⁶ ; Glu ²⁰⁵ ; Arg ¹²⁵
Cycloartenol	-10.06	42	His ⁷⁴⁰ ; Val ⁷¹¹ ; Asn ⁷¹⁰ ; Arg ⁶⁶⁹ ; Tyr ⁶⁶⁶ ; Tyr ⁶⁶² ; Val ⁶⁵⁶ ; Tyr ⁶³¹ ; Ser ⁶³⁰ ; Tyr ⁵⁴⁷ ; Arg ³⁵⁸ ; Phe ³⁵⁷ ; Ser ²⁰⁹ ; Val ²⁰⁷ ; Glu ²⁰⁶ ; Glu ²⁰⁵ ; Arg ¹²⁵
Cycloartenon	-10.48	21	His ⁷⁴⁰ ; Val ⁷¹¹ ; Asn ⁷¹⁰ ; Arg ⁶⁶⁹ ; Tyr ⁶⁶⁶ ; Tyr ⁶⁶² ; Trp ⁶⁵⁹ ; Val ⁶⁵⁶ ; Tyr ⁶³¹ ; Ser ⁶³⁰ ; Tyr ⁵⁴⁷ ; Arg ³⁵⁸ ; Phe ³⁵⁷ ; Ser ²⁰⁹ ; Val ²⁰⁷ ; Glu ²⁰⁶ ; Glu ²⁰⁵ ; Arg ¹²⁵

Contd..

Table 1: Contd...

Ligand	ΔG value (kcal/mol)	Inhibition constant (nM)	Interaction
Cycloartobiloxanton	-7.26	4780	Val ⁷¹¹ ; Asn ⁷¹⁰ ; Tyr ⁶⁷⁰ ; Arg ⁶⁶⁹ ; Tyr ⁶⁶⁶ ; Tyr ⁶⁶² ; Tyr ⁶³¹ ; Ser ⁶³⁰ ; Tyr ⁵⁴⁷ ; Arg ³⁵⁸ ; Phe ³⁵⁷ ; Ser ²⁰⁹ ; Val ²⁰⁷ ; Glu ²⁰⁶ ; Glu ²⁰⁵ ; Arg ¹²⁵
Cycloartocarpin	-7.04	6870	His ⁷⁴⁰ ; Val ⁷¹¹ ; Tyr ⁶⁶⁶ ; Tyr ⁶⁶² ; Trp ⁶⁵⁹ ; Val ⁶⁵⁶ ; Tyr ⁶³¹ ; Ser ⁶³⁰ ; Tyr ⁵⁴⁷ ; Arg ³⁵⁸ ; Phe ³⁵⁷ ; Ser ²⁰⁹ ; Phe ²⁰⁸ ; Val ²⁰⁷ ; Glu ²⁰⁶ ; Glu ²⁰⁵ ; Arg ¹²⁵
Cyclochampedol	-5.97	42060	Asn ⁷¹⁰ ; Arg ⁶⁶⁹ ; Tyr ⁶⁶⁶ ; Tyr ⁶⁶² ; Ser ⁶³⁰ ; Tyr ⁵⁴⁷ ; Arg ³⁵⁸ ; Phe ³⁵⁷ ; Ser ²⁰⁹ ; Val ²⁰⁷ ; Glu ²⁰⁶ ; Glu ²⁰⁵ ; His ¹²⁶ ; Arg ¹²⁵
Cyclocommunin	-8.06	1240	Val ⁷¹¹ ; Tyr ⁶⁶⁶ ; Tyr ⁶⁶² ; Trp ⁶⁵⁹ ; Val ⁶⁵⁶ ; Tyr ⁶³¹ ; Phe ³⁵⁷ ; Val ²⁰⁷ ; Glu ²⁰⁶ ; Glu ²⁰⁵ ; His ¹²⁶ ; Arg ¹²⁵
Cyclocommunol	-7.06	6720	His ⁷⁴⁰ ; Val ⁷¹¹ ; Asn ⁷¹⁰ ; Tyr ⁶⁶⁶ ; Tyr ⁶⁶² ; Tyr ⁶³¹ ; Ser ⁶³⁰ ; Ser ⁵⁵² ; Pro ⁵⁵⁰ ; Gly ⁵⁴⁹ ; Tyr ⁵⁴⁷ ; Phe ³⁵⁷ ; Ser ²⁰⁹ ; Glu ²⁰⁶ ; Glu ²⁰⁵ ; Arg ¹²⁵
Cycloeucalenol	-9.96	50	His ⁷⁴⁰ ; Val ⁷¹¹ ; Asn ⁷¹⁰ ; Arg ⁶⁶⁹ ; Tyr ⁶⁶⁶ ; Tyr ⁶⁶² ; Val ⁶⁵⁶ ; Tyr ⁶³¹ ; Ser ⁶³⁰ ; Tyr ⁵⁴⁷ ; Arg ³⁵⁸ ; Phe ³⁵⁷ ; Ser ²⁰⁹ ; Val ²⁰⁷ ; Glu ²⁰⁶ ; Glu ²⁰⁵ ; Arg ¹²⁵
Cycloheterofilin	-7.54	2990	Asn ⁷¹⁰ ; Tyr ⁶⁶⁶ ; Tyr ⁶⁶² ; Tyr ⁵⁸⁵ ; Cys ⁵⁵¹ ; Pro ⁵⁵⁰ ; Gly ⁵⁴⁹ ; Tyr ⁵⁴⁷ ; Arg ³⁵⁸ ; Phe ³⁵⁷ ; Arg ³⁵⁶ ; Ser ²⁰⁹ ; Phe ²⁰⁸ ; Glu ²⁰⁶ ; Glu ²⁰⁵ ; Arg ¹²⁵
Glutinol	-6.62	14130	Asn ⁷¹⁰ ; Tyr ⁶⁶⁶ ; Tyr ⁶⁶² ; Tyr ⁶³¹ ; Ser ⁶³⁰ ; Tyr ⁵⁴⁷ ; Phe ³⁵⁷ ; Ser ²⁰⁹ ; Glu ²⁰⁵ ; His ¹²⁶ ; Arg ¹²⁵
Heterofilin	-7.15	5760	Asn ⁷¹⁰ ; Arg ⁶⁶⁹ ; Tyr ⁶⁶⁶ ; Tyr ⁶⁶² ; Tyr ⁵⁸⁵ ; Ser ⁵⁵² ; Pro ⁵⁵⁰ ; Gly ⁵⁴⁹ ; Tyr ⁵⁴⁷ ; Arg ³⁵⁸ ; Phe ³⁵⁷ ; Ser ²⁰⁹ ; Val ²⁰⁷ ; Glu ²⁰⁶ ; Glu ²⁰⁵ ; Arg ¹²⁵
Heteroflavin A	-6.33	22800	Arg ⁶⁶⁹ ; Tyr ⁶⁶⁶ ; Ser ⁶³⁰ ; Tyr ⁵⁴⁷ ; Arg ³⁵⁸ ; Phe ³⁵⁷ ; Ser ²⁰⁹ ; Val ²⁰⁷ ; Glu ²⁰⁶ ; Glu ²⁰⁵ ; His ¹²⁶ ; Arg ¹²⁵
Heteroflavin C	-5.74	61750	Arg ⁶⁶⁹ ; Tyr ⁶⁶⁶ ; Ser ⁶³⁰ ; Tyr ⁵⁴⁷ ; Arg ³⁵⁸ ; Phe ³⁵⁷ ; Ser ²⁰⁹ ; Val ²⁰⁷ ; Glu ²⁰⁶ ; Glu ²⁰⁵ ; His ¹²⁶ ; Arg ¹²⁵
5'- Hydroxycudraflavin A	-8.33	788	His ⁷⁴⁰ ; Val ⁷¹¹ ; Arg ⁶⁶⁹ ; Tyr ⁶⁶⁶ ; Tyr ⁶⁶² ; Trp ⁶⁵⁹ ; Val ⁶⁵⁶ ; Tyr ⁶³¹ ; Ser ⁶³⁰ ; Arg ³⁵⁸ ; Phe ³⁵⁷ ; Ser ²⁰⁹ ; Val ²⁰⁷ ; Glu ²⁰⁶ ; Glu ²⁰⁵ ; Arg ¹²⁵
Morusin	-7.82	1850	His ⁷⁴⁰ ; Val ⁷¹¹ ; Tyr ⁶⁷⁰ ; Arg ⁶⁶⁹ ; Tyr ⁶⁶⁶ ; Tyr ⁶⁶² ; Trp ⁶⁵⁹ ; Tyr ⁶³¹ ; Ser ⁶³⁰ ; Tyr ⁵⁴⁷ ; Phe ³⁵⁷ ; Ser ²⁰⁹ ; Val ²⁰⁷ ; Glu ²⁰⁶ ; Glu ²⁰⁵ ; Arg ¹²⁵
Morusin Hydroperoxide	-7.94	1510	His ⁷⁴⁰ ; Val ⁷¹¹ ; Arg ⁶⁶⁹ ; Tyr ⁶⁶⁶ ; Tyr ⁶⁶² ; Trp ⁶⁵⁹ ; Val ⁶⁵⁶ ; Tyr ⁶³¹ ; Ser ⁶³⁰ ; Tyr ⁵⁴⁷ ; Phe ³⁵⁷ ; Ser ²⁰⁹ ; Val ²⁰⁷ ; Glu ²⁰⁶ ; Glu ²⁰⁵ ; His ¹²⁶ ; Arg ¹²⁵
Norartocarpin	-6.74	11550	His ⁷⁴⁰ ; Val ⁷¹¹ ; Asn ⁷¹⁰ ; Arg ⁶⁶⁹ ; Tyr ⁶⁶⁶ ; Tyr ⁶⁶² ; Tyr ⁶³¹ ; Ser ⁶³⁰ ; Gly ⁵⁴⁹ ; Tyr ⁵⁴⁷ ; Phe ³⁵⁷ ; Ser ²⁰⁹ ; Glu ²⁰⁶ ; Glu ²⁰⁵ ; Arg ¹²⁵

Table 2: ADME-Tox properties prediction of twelve best docking results using SWISSADME online tools software

Sample	MW	HBA	HBD	TPSA	XLOGP3	ESOL	Log Kp	MR	Csp3	NRB	RO5
24-Methylencycloartanon	875.44	1	0	17.07	9.99	2.99e-09	-1.88	138.99	0.90	5	1
Artoindonesianin A	570.67	7	3	109.36	7.83	5.46e-09	-4.22	167.24	0.40	5	1
Artoindonesianin A3	434.44	7	4	120.36	4.76	1.46e-06	-5.57	121.90	0.24	1	0
Artoindonesianin B	468.50	8	3	118.59	4.82	1.59e-06	-5.74	129.43	0.35	8	0
Artoindonesianin R	398.41	7	3	109.36	4.54	5.64e-06	-5.51	110.69	0.23	5	0
β -sitosterol	414.71	1	1	20.23	9.34	1.26e-08	-2.20	133.23	0.93	6	1
Cudraflavin C	422.47	6	4	101.13	5.55	9.82e-07	-4.94	123.45	0.24	5	0
Cycloartenol	426.72	1	1	20.23	9.78	4.14e-09	-1.96	135.14	0.93	4	1
Cycloartenon	424.70	1	0	17.07	9.46	6.78e-09	-2.17	134.18	0.90	4	1
Cyclocommunin	420.45	6	3	100.13	5.85	4.83e-07	-4.71	121.00	0.24	3	0
Cycloeucalenol	426.72	1	1	20.23	9.91	3.99e-09	-1.87	135.40	0.93	5	1
5'-Hydroxycudraflavin A	434.44	7	3	109.36	4.84	1.30e-06	-5.51	121.40	0.24	1	0

MW: Molecular weight, HBA: Acceptable H-bonds, HBD: Donatable H-bonds, TPSA: Topological polar surface area (TPSA < 140 Å² good intestinal absorptions and TPSA < 70 Å² good brain penetration), XLOGP3: Lipophilicity descriptor, ESOL: Estimated solubility in water, Log Kp: Skin permeant, MR: Molar refractivity, Csp3: The fraction of carbon in the sp³ hybridization, NRB: The number of rotatable bonds, RO5: The rule of five Lipinski rules

All phytocompounds showed the H-bond (acceptor and donor) and skin permeant value in the acceptable range. Based on the topological polar surface area (TPSA) value, which reveals that 24-methylencycloartanon, β -sitosterol, cycloartenol, cycloartenon, and cycloeucalenol have an excellent brain penetration (TPSA < 70 Å²), and seven other

compounds have good gastrointestinal penetration (with TPSA < 140 Å²).^[25] XLOGP3 shows the lipophilicity and polarity value prediction of phytocompounds. The higher the value, the lower the polarity.^[26,27] ESOL indicates the solubility levels of phytocompounds. The lower the values,^[28] the lower solubility.^[29] Figure 5 demonstrated that




Figure 4: Interaction visualization of twelve best docking results of phytocompounds from *Artocarpus champeden* against macromolecule of DPP-IV receptor. DPP-IV: Dipeptidyl peptidase IV

the phytocompounds of artonindonesianin (A3, B, and R), β -sitosterol, cycloartenol, and 5'-hydroxycudraflavon

A were the acceptable/optimal range of ADME-Tox/physicochemical space for oral bioavailability.




Figure 5: Bioavailability radar representation of the 12 best docking findings of *Artocarpus champeden* phytocompounds

CONCLUSION

Analysis of *in silico* molecular docking and ADME-Tox prediction were performed to study the potential pharmacological activity of phytocompounds from *A. champeden* as DPP-IV inhibitors. Our findings show that almost all phytocompounds have potential interaction with the receptor at the active subsites. Nevertheless, 12 phytocompounds have the most similar interaction with the DPP-IV receptor and have different physicochemical properties for bioavailability and pharmacokinetics prediction.

Financial support and sponsorship

Nil.

Conflicts of interest

There are no conflicts of interest.

REFERENCES

- de Almeida Lopes MM, de Souza CO, de Oliveira Silva E. Cempedak – *Artocarpus champeden*. *Exot Fruits* 2018;???:121-7.
- Achmad SA, Hakim EH, Juliawaty LD, Makmur L, Suyatno A. A new prenylated flavone from *Artocarpus champeden*. *J Nat Prod* 1996;59:878-9.
- Hakim EH, Juliawaty LD, Syah YM, Achmad SA. Molecular diversity of *Artocarpus champeden* (Moraceae): A species endemic to Indonesia. *Mol Divers* 2005;9:149-58.
- Syah YM, Juliawaty LD, Achmad SA, Hakim EH, Ghisalberti EL. Cytotoxic prenylated flavones from *Artocarpus champeden*. *J Nat Med* 2006;60:308-12.
- Widyawaruyanti A, Subeharjauni SK, Awale S, Nindatu M, Zaini NC, et al. New prenylated flavones from *Artocarpus champeden*, and their antimalarial activity *in vitro*. *J Nat Med* 2007;61:410-3.
- Arciniega M, Lange OF. Improvement of virtual screening results by docking data feature analysis. *J Chem Inf Model* 2014;54:1401-11.
- Morris GM, Ruth H, Lindstrom W, Sanner MF, Belew RK, Goodsell DS, et al. Software news and updates AutoDock4 and AutoDockTools4: Automated docking with selective receptor flexibility. *J Comput Chem* 2009;30:2785-91.
- Wang L, Wu Y, Deng Y, Kim B, Pierce L, Krilov G, et al. Accurate and reliable prediction of relative ligand binding potency in prospective drug discovery by way of a modern free-energy calculation protocol and force field. *J Am Chem Soc* 2015;137:2695-703.
- Belew RK, Forli S, Goodsell DS, O'Donnell TJ, Olson AJ. Fragment-based analysis of ligand dockings improves classification of actives. *J Chem Inf Model* 2016;56:1597-607.

10. Daina A, Michielin O, Zoete V. SwissADME: A free web tool to evaluate pharmacokinetics, drug-likeness and medicinal chemistry friendliness of small molecules. *Sci Rep* 2017;7:42717.
11. Pires DE, Blundell TL, Ascher DB. pkCSM: Predicting small-molecule pharmacokinetic and toxicity properties using graph-based signatures. *J Med Chem* 2015;58:4066-72.
12. Verma D, Mitra D, Paul M, Chaudhary P, Kamboj A, Thatoi H, et al. Potential inhibitors of SARS-CoV-2 (COVID 19) proteases PLpro and Mpro/3CLpro: Molecular docking and simulation studies of three pertinent medicinal plant natural components. *Curr Res Pharmacol Drug Discov* 2021;2:100038.
13. Prasetyanti IK, Sukardiman, Suharto. ADMET prediction and in silico analysis of mangostin derivatives and sinensetin on maltase-glucoamylase target for searching anti-diabetes drug candidates. *Pharmacogn J* 2021;13:883-889.
14. Abdurrahman S, Ruslin R, Hasanah AN, Mustarichie R. Molecular docking studies and ADME-Tox prediction of phytocompounds from *Merremia peltata* as a potential anti-alopecia treatment. *J Adv Pharm Technol Res* 2021;12:132-9.
15. Arunkumar J, Rajarajan S. Study on antiviral activities, drug-likeness and molecular docking of bioactive compounds of *Punica granatum* L. to Herpes simplex virus-2 (HSV-2). *Microb Pathog* 2018;118:301-9.
16. O'Boyle NM, Banck M, James CA, Morley C, Vandermeersch T, Hutchison GR. Open Babel: An open chemical toolbox. *J Cheminform* 2011;3:33.
17. Ahmad I, Arifianti AE, Sakti AS, Saputri FC, Mun'im A. Simultaneous natural deep eutectic solvent-based ultrasonic-assisted extraction of bioactive compounds of cinnamon bark and sappan wood as a dipeptidyl peptidase IV inhibitor. *Molecules* 2020;25:E3832.
18. Mahayasih PG, Harizal, Herman, I. In silico identification of natural products from *Centella asiatica* as severe acute respiratory syndrome coronavirus-2 main protease inhibitor. *J Adv Pharm Technol Res* 2021;12:261-6.
19. Kim BR, Kim HY, Choi I, Kim JB, Jin CH, Han AR. DPP-IV inhibitory potentials of flavonol glycosides isolated from the seeds of *Lens culinaris*: In vitro and molecular docking analyses. *Molecules* 2018;23:E1998.
20. Arulmozhiraja S, Matsuo N, Ishitsubo E, Okazaki S, Shimano H, Tokiwa H. Comparative binding analysis of dipeptidyl peptidase IV (DPP-4) with antidiabetic drugs – An Ab initio fragment molecular orbital study. *PLoS One* 2016;11:e0166275.
21. Luo F, Fu Y, Ma L, Dai H, Wang H, Chen H, et al. Exploration of dipeptidyl peptidase-IV (DPP-IV) inhibitory peptides from silkworm pupae (*Bombyx mori*) proteins based on in silico and in vitro assessments. *J Agric Food Chem* 2022;70:3862-71.
22. Zhang X, Wang R, Cheng C, Zhang Y, Ma Y, Lu W. Identification of two novel dipeptidyl peptidase-IV inhibitory peptides from sheep whey protein and inhibition mechanism revealed by molecular docking. *Food Biosci* 2022;48:101733.
23. Radifar M, Yuniarti N, Istyastono EP. PyPLIF: Python-based protein-ligand interaction fingerprinting. *Bioinformatics* 2013;9:325-8.
24. Lipinski CA, Lombardo F, Dominy BW, Feeney PJ. Experimental and computational approaches to estimate solubility and permeability in drug discovery and development settings. *Adv Drug Deliv Rev* 2001;46:3-26.
25. Daina A, Zoete V. A BOILED-egg to predict gastrointestinal absorption and brain penetration of small molecules. *ChemMedChem* 2016;11:1117-21.
26. Veber DF, Johnson SR, Cheng HY, Smith BR, Ward KW, Kopple KD. Molecular properties that influence the oral bioavailability of drug candidates. *J Med Chem* 2002;45:2615-23.
27. Ghaemi Z, Alberga D, Carloni P, Laio A, Lattanzi G. Permeability coefficients of lipophilic compounds estimated by computer simulations. *J Chem Theory Comput* 2016;12:4093-9.
28. Daina A, Michielin O, Zoete V. iLOGP: A simple, robust, and efficient description of n-octanol/water partition coefficient for drug design using the GB/SA approach. *J Chem Inf Model* 2014;54:3284-301.
29. Arnott JA, Planey SL. The influence of lipophilicity in drug discovery and design. *Expert Opin Drug Discov* 2012;7:863-75.

Author Queries???

- AQ1: Kindly provide part label in figure.
- AQ2: Kindly provide the author full name.
- AQ3: The author "Supandi" has not agreed to the copyright terms and conditions which was sent on the authors email address.
- AQ4: Kindly check the author name provided in New System "Herman Herman." Please confirm.
- AQ5: The author "Neneng Siti Silfi Ambarwati" has not agreed to the copyright terms and conditions which was sent on the authors email address.
- AQ6: Kindly check the author name provided in New System "Rosmalena Sofyan." Please confirm.
- AQ7: Kindly provide the department
- AQ8: Kindly check the affiliation.
- AQ9: Please provide publisher location.
- AQ10: Kindly provide author initial.